battery, secondary
premier batteries pty ltd - 34158 - battery, secondary - replacement nickel metal hydride battery for lifepak 20
pro vitality
neolife international pty ltd - glycine max, quantity: 225 mg (equivalent: linolenic acid, qty 16.65 mg); triticum aestivum, quantity: 150 mg (equivalent: gluten, qty 0 mg); triticum aestivum, quantity: 10 mg (equivalent: gluten, qty 0.004 mg); oryza sativa, quantity: 300 mg; oryza sativa, quantity: 10 mg; mixed (high-alpha type) tocopherols concentrate, quantity: 2 mg - capsule, soft - excipient ingredients: gelatin; yellow beeswax; titanium dioxide; chlorophyllin-copper complex; purified water; glycerol - antioxidant/reduce free radicals formed in the body ; maintain/support body metabolism/metabolic rate ; maintain/support energy production ; maintain/support eye health ; maintain/support healthy teeth ; anti-inflammatory/relieve inflammation ; maintain/support connective tissue health ; helps enhance/promote bone health ; maintain/support bone health ; helps enhance/promote healthy joint function ; maintain/support joint health ; maintain/support cardiovascular system health ; maintain/support healthy cardiovascular system function ; maintain/support heart health ; maintain/support immune system health ; maintain/support healthy immune system function ; maintain/support muscle health ; maintain/support muscle function ; helps maintain/support cellular uptake of (state vitamin/mineral/nutrient) ; helps prevent dietary (state vitamin/mineral/nutrient) deficiency ; maintain/support brain function ; maintain/support nervous system health ; maintain/support nervous system function
blooms the chemist clopidogrel clopidogrel 75mg (as hydrogen sulfate) tablets blister pack
apotex pty ltd - clopidogrel hydrogen sulfate -
plidogrel clopidogrel (as besilate) 75 mg tablet blister pack
arrotex pharmaceuticals pty ltd - clopidogrel besilate, quantity: 112.1 mg (equivalent: clopidogrel, qty 75 mg) - tablet, film coated - excipient ingredients: mannitol; polyethylene glycol monomethyl ether; iron oxide red; stearic acid; hyprolose; purified talc; citric acid monohydrate; hypromellose; lactose monohydrate; microcrystalline cellulose; triacetin; crospovidone; titanium dioxide - prevention of vascular ischaemia associated with atherothrombotic events (myocardial infarction, stroke and vascular death) in patients with a history of symptomatic atherosclerotic disease. acute coronary syndrome: plidogrel is indicated in combination with aspirin for patients with: unstable angina or non-st-elevation myocardial infarction in order to prevent early and long-term atherothrombotic events (myocardial infarction, stroke, vascular death or refractory ischaemia). plidogrel is indicated for the treatment of acute coronary syndrome whether or not patients undergo cardiac revascularisation (surgical or pci, with or without stent); st-segment elevation acute myocardial infarction in order to prevent atherothrombotic events. in this population, plidogrel has been shown to reduce the rate of death from any cause and the rate of a combined endpoint of death, re-infarction or stroke in medically treated patients eligible for thrombolytic therapy.
clopidogrel rbx clopidogrel (as hydrogen sulfate) 75 mg tablet blister pack
sun pharma anz pty ltd - clopidogrel hydrogen sulfate -
clopidogrel-drla clopidogrel 75 mg tablet blister pack
dr reddys laboratories australia pty ltd - clopidogrel -
clopidogrel apotex clopidogrel (as besilate) 75 mg film-coated tablet blister pack
southern cross pharma pty ltd - clopidogrel besilate, quantity: 111.86 mg (equivalent: clopidogrel, qty 75 mg) - tablet, film coated - excipient ingredients: mannitol; microcrystalline cellulose; colloidal anhydrous silica; stearic acid; hypromellose; titanium dioxide; iron oxide red - prevention of vascular ischaemia associated with atherothrombotic events (myocardial infarction, stroke and vascular death) in patients with a history of symptomatic atherosclerotic disease.,acute coronary syndrome,clopidogrel is indicated in combination with aspirin for patients with,-unstable angina or non-st-elevation myocardial infarction in order to prevent early and long-termatherothrombotic events (myocardial infarction, stroke, vascular death or refractory ischaemia). clopidogrel is indicated for the treatment of acute coronary syndrome whether or not patients undergo cardiac revascularisation (surgical or pci, with or without stent).,- st-segment elevation acute myocardial infarction in order to prevent atherothrombotic events. in thispopulation, clopidogrel has been shown to reduce the rate of death from any cause and the rate of a combined endpoint of death, re-infarction or stroke in medically treated patients eligible for thrombolytic therapy.
clopidogrel sanofi clopidogrel (as hydrogen sulfate) 300 mg tablet blister pack
sanofi-aventis australia pty ltd - clopidogrel hydrogen sulfate -
clopidogrel winthrop clopidogrel (as hydrogen sulfate) 300 mg tablet blister pack
sanofi-aventis australia pty ltd - clopidogrel hydrogen sulfate -
clopidogrel sanofi clopidogrel (as hydrogen sulfate) 75 mg tablet blister pack
sanofi-aventis australia pty ltd - clopidogrel hydrogen sulfate -